Opendata, web and dolomites

OMVCRC

Engineered bacterial Outer Membrane Vesicles (OMVs) for colorectal cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OMVCRC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI TRENTO 

Organization address
address: VIA CALEPINA 14
city: TRENTO
postcode: 38122
website: www.unitn.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI TRENTO IT (TRENTO) coordinator 93˙750.00
2    FONDAZIONE TOSCANA LIFE SCIENCES IT (SIENA) participant 56˙250.00

Map

 Project objective

This proposal originates from recent results obtained in the course of the Advanced ERC Project “OMVac”, the scope of which is to exploit the unique adjuvanticity properties of bacterial Outer Membrane Vesicles (OMVs) for developing innovative vaccines against infectious diseases and cancer. In particular, Synthetic Biology was applied to engineer OMVs with FAT1, a tumour associated antigen expressed in most primary and metastatic colorectal cancers (CRC). Using cancer models in immunocompetent mice, immunization with FAT1-decorated OMVs inhibited subcutaneous growth of FAT1-positive CT26 cancer cells and protection correlated with an increase in tumour infiltration of CD4/CD8 T cells and concomitant decrease of Treg and MDSCs. These promising results prompted the submission of the present proposal which has as main objectives: 1) the demonstration that FAT1-OMV immunization can synergise with the protective activity of checkpoint inhibitors, and 2) the development of a scalable FAT1-OMV production and purification process which could allow testing FAT1-OMV/checkpoint inhibitor combination in the clinical setting.

 Publications

year authors and title journal last update
List of publications.
2018 Alberto Grandi, Laura Fantappiè, Carmela Irene, Silvia Valensin, Michele Tomasi, Simone Stupia, Riccardo Corbellari, Elena Caproni, Ilaria Zanella, Samine J. Isaac, Luisa Ganfini, Luca Frattini, Enrico König, Assunta Gagliardi, Simona Tavarini, Chiara Sammicheli, Matteo Parri, Guido Grandi
Vaccination With a FAT1-Derived B Cell Epitope Combined With Tumor-Specific B and T Cell Epitopes Elicits Additive Protection in Cancer Mouse Models
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00481
Frontiers in Oncology 8 2020-01-21

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OMVCRC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OMVCRC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More